MX2019000935A - Metodos para cuantificar anticuerpos individuales de una mezcla. - Google Patents
Metodos para cuantificar anticuerpos individuales de una mezcla.Info
- Publication number
- MX2019000935A MX2019000935A MX2019000935A MX2019000935A MX2019000935A MX 2019000935 A MX2019000935 A MX 2019000935A MX 2019000935 A MX2019000935 A MX 2019000935A MX 2019000935 A MX2019000935 A MX 2019000935A MX 2019000935 A MX2019000935 A MX 2019000935A
- Authority
- MX
- Mexico
- Prior art keywords
- mixture
- antibody molecule
- antibody
- quantitating
- antibody molecules
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 abstract 1
- 238000002169 hydrotherapy Methods 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/30—Partition chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción se relaciona con, inter alia, un método para cuantificar una cantidad de una molécula de anticuerpo de una mezcla que comprende dos o más moléculas de anticuerpo, que comprenden cada una de dos o más moléculas de anticuerpo de la mezcla por cromatografía de interacción hidrofóbica cromatografía de líquidos de alta resolución (HIC-HPLC) y cuantificación de una cantidad de cada molécula de anticuerpo, donde el peso molecular de cada molécula de anticuerpo está dentro de 15 kDa de cualquier otra molécula de anticuerpo en la mezcla y cualquier molécula de anticuerpo es diferente de otra molécula de anticuerpo en la mezcla en más de aproximadamente 0.25 unidades sobre la escala de hidropatía de Kyte Doolittle o cada una de las moléculas de anticuerpo cuando se ensayan solas en HIC-HPLC eluyen a un tiempo de ensayo distinto con poca superposición de las otras moléculas de anticuerpo en la mezcla, o ambas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662375887P | 2016-08-16 | 2016-08-16 | |
PCT/US2017/045855 WO2018034885A1 (en) | 2016-08-16 | 2017-08-08 | Methods for quantitating individual antibodies from a mixture |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000935A true MX2019000935A (es) | 2019-07-04 |
Family
ID=59702834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000935A MX2019000935A (es) | 2016-08-16 | 2017-08-08 | Metodos para cuantificar anticuerpos individuales de una mezcla. |
Country Status (14)
Country | Link |
---|---|
US (5) | US11020686B2 (es) |
EP (2) | EP3500297A1 (es) |
JP (2) | JP2019529350A (es) |
KR (3) | KR102511050B1 (es) |
CN (1) | CN109641050A (es) |
AU (1) | AU2017312785A1 (es) |
BR (1) | BR112019000872A2 (es) |
CA (1) | CA3031742A1 (es) |
EA (1) | EA201990317A1 (es) |
IL (2) | IL264631B2 (es) |
MX (1) | MX2019000935A (es) |
MY (1) | MY196321A (es) |
SG (1) | SG11201900201YA (es) |
WO (1) | WO2018034885A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス, インク.Flodesign Sonics, Inc. | 音響による親和性細胞抽出 |
SG11202003907WA (en) | 2017-12-14 | 2020-05-28 | Flodesign Sonics Inc | Acoustic transducer drive and controller |
CA3104390A1 (en) * | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
EP3886921A4 (en) * | 2018-11-30 | 2022-11-23 | Actinium Pharmaceuticals, Inc. | ACTINIUM 225 AND ACTINIUM 227 CONJUGATED ANTIBODIES, COMPOSITIONS AND METHODS RELATED |
EA202191961A1 (ru) * | 2019-01-16 | 2021-12-13 | Ридженерон Фармасьютикалз, Инк. | Способ и система идентификации и количественного определения фрагментации антител |
CA3192925A1 (en) | 2020-04-02 | 2021-03-11 | Regeneron Pharamaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
CN113588582B (zh) * | 2020-04-30 | 2024-05-14 | 上海药明生物技术有限公司 | 蛋白质样品浓度测定方式选择法及测定方法 |
CA3181026A1 (en) | 2020-06-03 | 2021-12-09 | Samit GANGULY | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
CN114577885B (zh) * | 2020-12-01 | 2024-03-29 | 齐鲁制药有限公司 | 一种检测重组组合抗体含量比例、电荷异质性和/或等电点的方法 |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801726A (en) | 1986-04-15 | 1989-01-31 | Northeastern University | Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin |
US4937188A (en) | 1986-04-15 | 1990-06-26 | Northeastern University | Enzyme activity amplification method for increasing assay sensitivity |
US5190864A (en) | 1986-04-15 | 1993-03-02 | Northeastern University | Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material |
US5412083A (en) | 1992-04-16 | 1995-05-02 | Northeastern University | Carbohydrate heterobifunctional cross-linking reagent |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
WO1996025425A1 (en) | 1995-02-16 | 1996-08-22 | Massachusetts Health Research Institute, Inc. | Purified tetanus toxoid and toxin |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
DE69922740T2 (de) | 1998-05-11 | 2005-12-08 | Tosoh Corp., Shinnanyo | Methode zur Trennung von Nucleinsäuren mittels Flüssigchromatographie |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
US7101982B2 (en) | 2001-03-30 | 2006-09-05 | Immunex Corporation | Control of ph transitions during chromatography |
AU2003268210A1 (en) | 2002-08-28 | 2004-03-19 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
JP2006507249A (ja) | 2002-09-13 | 2006-03-02 | バイオジェン アイデック インコーポレイテッド | 疑似移動床式クロマトグラフィーによる、ポリペプチドを精製する方法 |
SE0300612D0 (sv) * | 2003-03-05 | 2003-03-05 | Amersham Biosciences Ab | A method of preparing ligands for hydrophobic interaction chromatography |
JPWO2004087761A1 (ja) | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
JP5068072B2 (ja) | 2003-06-27 | 2012-11-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 連結ペプチドを含む改変された結合分子 |
US7427659B2 (en) | 2003-10-24 | 2008-09-23 | Amgen Inc. | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
US8084032B2 (en) | 2004-01-21 | 2011-12-27 | Ajinomoto Co., Inc. | Purification method which prevents denaturation of an antibody |
US7750129B2 (en) | 2004-02-27 | 2010-07-06 | Ge Healthcare Bio-Sciences Ab | Process for the purification of antibodies |
SE0400501D0 (sv) | 2004-02-27 | 2004-02-27 | Amersham Biosciences Ab | Antibody purification |
SE0400886D0 (sv) | 2004-04-02 | 2004-04-02 | Amersham Biosciences Ab | Process of purification |
US7795405B2 (en) | 2004-08-09 | 2010-09-14 | Guild Associates, Inc. | Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis |
US20060027454A1 (en) | 2004-08-09 | 2006-02-09 | Dinovo Augustine | Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis |
AU2005296351B2 (en) | 2004-10-21 | 2010-12-02 | Cytiva Bioprocess R&D Ab | A method of antibody purification |
WO2006088650A2 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
WO2007064281A1 (en) | 2005-12-02 | 2007-06-07 | Ge Healthcare Bio-Sciences Ab | Hydrophobic interaction chromatography |
KR20080104160A (ko) | 2006-03-28 | 2008-12-01 | 에프. 호프만-라 로슈 아게 | 항-igf-1r 인간 단일클론 항체 제형 |
SG10201406358SA (en) | 2006-04-05 | 2014-12-30 | Abbvie Biotechnology Ltd | Antibody purification |
SI2364691T1 (sl) | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
US9766217B2 (en) | 2006-09-08 | 2017-09-19 | Novo Nordisk A/S | Methods of optimizing chromatographic separation of polypeptides |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
ATE529752T1 (de) * | 2006-12-21 | 2011-11-15 | Novartis Ag | Antikörperquantifizierung |
US20080299545A1 (en) | 2007-03-06 | 2008-12-04 | Shuyuan Zhang | Chromatographic methods for assessing adenovirus purity |
US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
WO2009058769A1 (en) | 2007-10-30 | 2009-05-07 | Schering Corporation | Purification of antibodies containing hydrophobic variants |
EP2252952B1 (en) | 2008-01-25 | 2019-03-13 | Biogen MA Inc. | Automated system and method for monitoring chromatography column performance, and applications thereof |
US8410928B2 (en) | 2008-08-15 | 2013-04-02 | Biogen Idec Ma Inc. | Systems and methods for evaluating chromatography column performance |
US20100069617A1 (en) | 2008-09-12 | 2010-03-18 | Ge Healthcare Bio-Sciences Ab | Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions |
ES2535734T3 (es) | 2008-10-20 | 2015-05-14 | Abbvie Inc. | Aislamiento y purificación de anticuerpos mediante cromatografía de afinidad con la proteína A |
TW201028433A (en) | 2008-10-20 | 2010-08-01 | Abbott Lab | Viral inactivation during purification of antibodies |
SG175188A1 (en) | 2009-05-04 | 2011-11-28 | Abbott Biotech Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
PT3444335T (pt) | 2009-06-16 | 2021-07-12 | Genzyme Corp | Métodos melhorados para puruficação de vetores aav recombinantes |
BR112012001843A2 (pt) * | 2009-07-30 | 2016-03-15 | Hoffmann La Roche | separador de coluna de cromatografia móvel |
WO2011028961A2 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
EP3037104B1 (en) | 2009-10-20 | 2020-05-27 | AbbVie Inc. | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
US8246833B2 (en) | 2009-12-17 | 2012-08-21 | Ge Healthcare Bio-Sciences Ab | Chromatography column and maintenance method |
EA201201132A1 (ru) | 2010-02-12 | 2013-03-29 | ДСМ АйПи АССЕТС Б.В. | Очистка антител с помощью единого функционального блока |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
HUE029457T2 (en) | 2010-11-11 | 2017-02-28 | Abbvie Biotechnology Ltd | Liquid formulations containing a high concentration of ANTI-TNF-alpha antibody |
JP6088435B2 (ja) | 2010-12-15 | 2017-03-01 | バクスアルタ ゲーエムベーハー | 導電率グラディエントを用いる溶出液収集 |
EP2500073A1 (en) * | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
WO2013088259A2 (en) | 2011-10-19 | 2013-06-20 | Novimmune S.A. | Methods of purifying antibodies |
WO2013066707A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Chromatography process for resolving heterogeneous antibody aggregates |
KR102048189B1 (ko) | 2011-11-14 | 2019-11-25 | 리제너론 파아마슈티컬스, 인크. | Gdf8 및/또는 액티빈 a를 특이적으로 길항함으로써 근육량과 근육 강도를 증가시키는 조성물 및 방법 |
SG11201402485UA (en) | 2011-11-21 | 2014-06-27 | Genentech Inc | Purification of anti-c-met antibodies |
DK2791176T3 (en) | 2011-12-15 | 2018-10-15 | Prestige Biopharma Pte Ltd | PROCEDURE FOR CLEANING ANTIBODIES |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US20130336957A1 (en) | 2012-05-21 | 2013-12-19 | Abbvie, Inc. | Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography |
US20140154270A1 (en) | 2012-05-21 | 2014-06-05 | Chen Wang | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
WO2014025771A2 (en) | 2012-08-06 | 2014-02-13 | Biogen Idec Ma Inc. | Methods and compositions for inactivating enveloped viruses |
US9650411B2 (en) | 2012-08-07 | 2017-05-16 | Kyowa Hakko Kirin Co., Ltd. | Method of purifying protein |
WO2014100143A2 (en) | 2012-12-20 | 2014-06-26 | Medimmune, Llc | Liquid antibody formulation with improved aggregation properties |
JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
MX2015012114A (es) | 2013-03-08 | 2016-01-12 | Genzyme Corp | Fabricacion continua integrada de principios activos proteinicos terapeuticos. |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
US10118971B2 (en) * | 2013-03-13 | 2018-11-06 | Ibentrus, Inc. | Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor |
SG11201504260UA (en) | 2013-03-14 | 2015-10-29 | Abbvie Inc | Low acidic species compositions and methods for producing and using the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014145744A1 (en) | 2013-03-15 | 2014-09-18 | Alder Biopharmaceuticals, Inc. | Antibody purification and purity monitoring |
JP2016519070A (ja) * | 2013-03-15 | 2016-06-30 | アッヴィ・インコーポレイテッド | 抗体薬物複合体(adc)の精製 |
PL2970378T3 (pl) | 2013-03-15 | 2021-12-06 | Biogen Ma Inc. | Chromatografia oddziaływań hydrofobowych białek w warunkach bez soli |
SG10201913751RA (en) | 2013-05-06 | 2020-03-30 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TWI682780B (zh) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
KR101569783B1 (ko) | 2013-06-05 | 2015-11-19 | 한화케미칼 주식회사 | 항체의 정제 방법 |
US9150938B2 (en) | 2013-06-12 | 2015-10-06 | Orochem Technologies, Inc. | Tagatose production from deproteinized whey and purification by continuous chromatography |
TWI596107B (zh) | 2013-06-25 | 2017-08-21 | 卡地拉保健有限公司 | 單株抗體之新穎純化方法 |
US20150093800A1 (en) | 2013-09-05 | 2015-04-02 | Genentech, Inc. | Method for chromatography reuse |
EP3683232A1 (en) | 2013-09-13 | 2020-07-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
CA3174012A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
EP3060578A4 (en) | 2013-10-25 | 2017-07-05 | Medlmmune, LLC | Antibody purification |
US10115576B2 (en) | 2013-12-12 | 2018-10-30 | Waters Technologies Corporation | Method and an apparatus for analyzing a complex sample |
JO3701B1 (ar) * | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
FR3025515B1 (fr) | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | Procede de purification d'un anticorps monoclonal |
TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
JP2017536391A (ja) | 2014-12-02 | 2017-12-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−6rアンタゴニストを投与することによってドライアイ疾患を治療するための方法 |
EP3247718B1 (en) | 2015-01-21 | 2021-09-01 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
SG10202005670TA (en) | 2015-12-22 | 2020-07-29 | Regeneron Pharma | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer |
EP3394102A1 (en) | 2015-12-22 | 2018-10-31 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia |
EP3184119A1 (en) | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
GB201602938D0 (en) | 2016-02-19 | 2016-04-06 | Ucb Biopharma Sprl | Protein purification |
KR102461234B1 (ko) | 2016-06-14 | 2022-10-28 | 바이오젠 엠에이 인코포레이티드 | 올리고뉴클레오타이드의 정제를 위한 소수성 상호 작용 크로마토그래피 |
WO2018027195A1 (en) | 2016-08-05 | 2018-02-08 | Abbvie Biotherapeutics Inc. | Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same |
US10626376B2 (en) | 2016-11-14 | 2020-04-21 | St. Jude Children's Research Hospital | Method for isolating and purifying adeno-associated virus particles using salt |
WO2019040671A1 (en) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT |
WO2019178495A1 (en) | 2018-03-16 | 2019-09-19 | Biogen Ma Inc. | Methods for purifying recombinant adeno-associated viruses |
JP7462566B2 (ja) | 2018-03-16 | 2024-04-05 | ブリストル-マイヤーズ スクイブ カンパニー | タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元 |
JP2021519752A (ja) | 2018-03-29 | 2021-08-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 単量体モノクローナル抗体を精製する方法 |
JP2021528425A (ja) | 2018-06-19 | 2021-10-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | クロマトグラフィーを用いたタンパク質の精製方法 |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
WO2020023566A1 (en) | 2018-07-25 | 2020-01-30 | Merck Sharp & Dohme Corp. | Methods of separating host cell lipases from a production protein in chromatographic processes |
JP2021534151A (ja) | 2018-08-15 | 2021-12-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 下流クロマトグラフィーにおける再酸化によるタンパク質断片化制御戦略 |
US20220017570A1 (en) | 2018-11-05 | 2022-01-20 | Bristol-Meyers Squibb Company | Method for purifying pegylated protein |
US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
WO2020205469A1 (en) | 2019-03-29 | 2020-10-08 | Bristol-Myers Squibb Company | Methods of measuring hydrophobicity of chromatographic resins |
CN114173827A (zh) | 2019-06-28 | 2022-03-11 | 武田药品工业株式会社 | 腺相关病毒纯化方法 |
-
2017
- 2017-08-08 BR BR112019000872-1A patent/BR112019000872A2/pt unknown
- 2017-08-08 EA EA201990317A patent/EA201990317A1/ru unknown
- 2017-08-08 EP EP17757957.0A patent/EP3500297A1/en not_active Withdrawn
- 2017-08-08 JP JP2019505225A patent/JP2019529350A/ja active Pending
- 2017-08-08 MX MX2019000935A patent/MX2019000935A/es unknown
- 2017-08-08 KR KR1020227005544A patent/KR102511050B1/ko active IP Right Grant
- 2017-08-08 AU AU2017312785A patent/AU2017312785A1/en active Pending
- 2017-08-08 CA CA3031742A patent/CA3031742A1/en active Pending
- 2017-08-08 IL IL264631A patent/IL264631B2/en unknown
- 2017-08-08 KR KR1020237008775A patent/KR20230041834A/ko not_active Application Discontinuation
- 2017-08-08 SG SG11201900201YA patent/SG11201900201YA/en unknown
- 2017-08-08 KR KR1020197004613A patent/KR102369014B1/ko active IP Right Grant
- 2017-08-08 WO PCT/US2017/045855 patent/WO2018034885A1/en unknown
- 2017-08-08 EP EP22208008.7A patent/EP4183414A1/en active Pending
- 2017-08-08 US US16/322,292 patent/US11020686B2/en active Active
- 2017-08-08 MY MYPI2021007750A patent/MY196321A/en unknown
- 2017-08-08 IL IL309453A patent/IL309453A/en unknown
- 2017-08-08 CN CN201780050583.0A patent/CN109641050A/zh active Pending
-
2020
- 2020-10-21 US US17/076,307 patent/US11369896B2/en active Active
-
2021
- 2021-05-17 US US17/321,663 patent/US11571636B2/en active Active
-
2022
- 2022-08-04 JP JP2022124958A patent/JP2022159388A/ja active Pending
- 2022-12-19 US US18/067,803 patent/US11850535B2/en active Active
-
2023
- 2023-08-30 US US18/458,482 patent/US20230415073A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL264631B1 (en) | 2024-01-01 |
US20190184312A1 (en) | 2019-06-20 |
US20230119592A1 (en) | 2023-04-20 |
SG11201900201YA (en) | 2019-02-27 |
JP2019529350A (ja) | 2019-10-17 |
AU2017312785A1 (en) | 2019-01-24 |
KR20220025943A (ko) | 2022-03-03 |
US11571636B2 (en) | 2023-02-07 |
KR20230041834A (ko) | 2023-03-24 |
KR20190039144A (ko) | 2019-04-10 |
US11850535B2 (en) | 2023-12-26 |
US20210268404A1 (en) | 2021-09-02 |
MY196321A (en) | 2023-03-24 |
US20210031123A1 (en) | 2021-02-04 |
IL309453A (en) | 2024-02-01 |
EA201990317A1 (ru) | 2019-07-31 |
CN109641050A (zh) | 2019-04-16 |
EP4183414A1 (en) | 2023-05-24 |
EP3500297A1 (en) | 2019-06-26 |
US11020686B2 (en) | 2021-06-01 |
US11369896B2 (en) | 2022-06-28 |
IL264631B2 (en) | 2024-05-01 |
IL264631A (en) | 2019-02-28 |
WO2018034885A1 (en) | 2018-02-22 |
US20230415073A1 (en) | 2023-12-28 |
KR102511050B1 (ko) | 2023-03-17 |
JP2022159388A (ja) | 2022-10-17 |
KR102369014B1 (ko) | 2022-03-02 |
BR112019000872A2 (pt) | 2019-04-30 |
CA3031742A1 (en) | 2018-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY196321A (en) | Methods for Quantitating Individual Antibodies From a Mixture | |
BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
BR112018001530A2 (pt) | anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica | |
MX2021013681A (es) | Moleculas de union a lag-3 y metodos de uso de las mismas. | |
AR096713A1 (es) | Proceso de purificación para anticuerpos monoclonales | |
SA520412669B1 (ar) | تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية | |
BR112016013347A8 (pt) | anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos. | |
UA117575C2 (uk) | Антитіло, яке специфічно зв'язується з il-17a та його застосування | |
MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
SE1851019A1 (en) | Ionic liquids for the modification of nanocellulose film | |
WO2015193325A3 (en) | Ceramides and their use in diagnosing cvd | |
FR3034430A1 (fr) | Lignee cellulaire surexprimant l'antigene cd303 humain | |
PE20190415A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos | |
MX2016017115A (es) | Metodos y reactivos para la purificacion de proteinas. | |
BR112016030950A2 (pt) | polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. | |
EP4306544A3 (en) | Production of heteromultimeric proteins using mammalian cells | |
ZA201904097B (en) | Anti-il-5 antibodies | |
EA202190163A1 (ru) | Системы и способы получения полипептида из смеси | |
WO2016061608A8 (en) | Monoclonal ανti-gpc-1 antibodies and uses thereof | |
ZA202104048B (en) | Anti-il-17a antibody and use thereof | |
WO2015051079A3 (en) | Phosphohistidine mimetics and antibodies to same | |
MY197202A (en) | A liquid formulation of anti-tnf alpha antibody | |
BR112015028050A2 (pt) | plantas que possuem uma ou mais características relativas a rendimento aprimoradas e método de sua elaboração | |
AU2018273799A1 (en) | Novel murine parvovirus and uses therefor | |
WO2018226098A3 (en) | METHODS OF TYPING NEUROLOGICAL DISORDERS AND CANCER, AND DEVICES THEREOF |